BioXcel and Takeda Partner to Repurpose Assets for Orphan Diseases

BioXcel and Takeda Partner to Repurpose Assets for Orphan Diseases

BRANFORD, Conn., April 9, 2015 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in providing cloud-based Pharma big data solutions for discovering novel products, announced today that it has entered into a partnership with Takeda Development Center Americas ("Takeda"), for the repurposing of assets across the gamut of rare diseases. Through this partnership, Takeda, a global research-based company with a focus on innovation in medicine for the health of people worldwide, will gain access to and leverage BioXcel's Big Data Innovation Lab -- an integrated product discovery engine -- and PharmGPS(TM) Orphan Disease Suite for drug discovery and repurposing.

Commenting on the partnership, BioXcel's CEO and Chairman, Vimal Mehta, Ph.D., said, "We are pleased that Takeda will leverage our expertise in rare and ultra rare diseases to support their innovation and portfolio expansion initiatives. Discovering novel applications for existing molecules is an increasingly attractive strategy to address patient needs, while capitalizing on previous investments and de-risking clinical development. Our Big Data Innovation Lab facilitates the repurposing of the most attractive candidates applicable to a given disease."

About PharmGPS(TM) Orphan Disease Suite:

A live and multi-dimensional platform, BioXcel's proprietary suite encompasses more than 9,000 rare and ultra-rare diseases, 4,000-5,000 associated genes, 1,500 disease pathways, and distinct target-indication tiles for antibody, protein, RNA, small molecule and gene therapy modalities. Partners can make informed decisions related to rare disease indications, and associate the ideal mode of pharmacotherapy, factoring in strategic, medical, scientific and commercial considerations. The suite enables the commercialization of orphan drugs via de novo drug discovery, or repurposing and reformulation of clinical assets (drug rescue) based on disease severity, gene ontology, disease pathways, proteinopathy, standard of care, emerging innovation, enabling technologies, and current drug pipeline -- all of which are crucial when addressing the high unmet need of patients with rare and ultra rare diseases.

About BioXcel:

BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS(TM) - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and an executive team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.


BioXcel Corporation
Anita Ganjoo
Corporate Communications
Email: [email protected]
The Ruth Group for BioXcel
Lee Roth (Investors) / Iman Oubou (Media)
Email: [email protected] / [email protected]
Tel: 646 536 7012 / 646 536 7029